logo
Insomnia could be reason behind reduced quality of life among people with ADHDL: Study

Insomnia could be reason behind reduced quality of life among people with ADHDL: Study

Time of India15-07-2025
New Delhi: Insomnia, or sleep disturbances, arising out of ADHD's impulsivity could be the reason why adults with ADHD symptoms experience a reduced quality of life, according to a new study.
Usually diagnosed during childhood and teenage,
attention deficit hyperactivity disorder
(ADHD) is marked with restlessness, hyperactivity, and short attention spans. It is the neuro-developmental disorder linked with a delayed maturing of prefrontal cortex of the brain, which is crucial for attention and focus.
Researchers, led by those from the University of Southampton, UK, and the Netherlands Institute for Neuroscience, found that ADHD symptoms of inattention and hyperactivity in adults were associated with more severe insomnia, a lower sleep quality and preference for going to bed and waking up late.
The study, published in the British Medical Journal (BMJ) Mental Health, looked at data from the Netherlands Sleep Registry, an online survey of more than ten thousand adult participants.
Responses from 1,364 middle-aged and older adult participants on questions about ADHD traits, sleep disturbances, circadian factors, depression and quality of life were analysed.
"We know that sleep disruption can impact neurobehavioural and cognitive systems, including attention and emotional regulation. At the same time, sleep disruption may arise from ADHD-related impulsivity and hyperactivity, suggesting a reinforcing cycle between sleep disorders and ADHD," senior author Sarah L Chellappa, associate professor of psychology at the University of Southampton, said.
People with ADHD are diagnosed with sleep disorder about eight times more than the general population, which can show up as a delayed onset of sleep, moving more while asleep, daytime sleepiness or a shorter night-time sleep, the authors said.
"We show that adult ADHD traits and insomnia severity were significant predictors of lower (quality of life) and that insomnia severity mediated this association," they wrote.
Differences in cognition or thought processes among people with ADHD, along with those in sleep and body clock-related genes in ADHD could be potential mechanisms, the team said.
"Adults with ADHD traits may be more likely to have low sleep quality, insomnia complaints, and low mood levels, all of which lead to reduced life satisfaction," co-author Samuele Cortese from the University of Southampton said.
"There needs to be more research to understand this complex interplay. By improving our understanding, we could uncover treatment options that improve the quality of life of people with ADHD," Cortese said. PTI
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sun Pharma, Lupin, Dr Reddy's recall products in US due to mfg issues
Sun Pharma, Lupin, Dr Reddy's recall products in US due to mfg issues

Business Standard

timea day ago

  • Business Standard

Sun Pharma, Lupin, Dr Reddy's recall products in US due to mfg issues

Domestic drug majors Sun Pharma, Lupin and Dr Reddy's Laboratories are recalling drugs in the US market due to manufacturing issues and product mix up, according to the US health regulator. As per the latest Enforcement Report of US Food and Drug Administration (USFDA), the Mumbai-headquartered Sun Pharmaceutical Industries is recalling 5,448 bottles of a generic medication in the US. Princeton-based Sun Pharmaceutical Industries Inc is recalling the affected lot of Lisdexamfetamine Dimesylate capsules (60 mg) due to "Failed Dissolution Specifications", the US health regulator stated. The medication is used to treat attention deficit hyperactivity disorder (ADHD). The drug firm initiated the Class II recall in the US on June 16 this year, it added. Another Mumbai-based drug maker Lupin is recalling 58,968 bottles of a generic combination medication used to treat high blood pressure. Naples-based Lupin Pharmaceuticals Inc is recalling Lisinopril and Hydrochlorothiazide tablets (USP 20mg/12.5mg). The affected lot was manufactured at the company's Nagpur-based manufacturing facility. As per the USFDA, the company initiated the Class II recall on June 20 due to "Product Mix Up". This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg, the US health regulator stated. In another filing, the US health regulator said that Dr Reddy's Laboratories is recalling 1,476 bottles of Omeprazole Delayed-release capsules. The medication is used to treat certain stomach and esophagus problems. Princeton-based Dr. Reddy's Laboratories, Inc initiated the Class II recall on June 30, 2025, USFDA stated. The affected lot was produced at the company's Bachupally (Telangana)-based manufacturing facility. The recall is due to the presence of foreign tablets/capsules, USFDA said. It is due to the presence of foreign Divalproex Sodium extended-release 250mg tablets in a bottle of omeprazole capsules, it added. As per the USFDA, a Class-II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal.

Sun Pharma, Lupin, Dr Reddy's recall products in US market due to manufacturing issues
Sun Pharma, Lupin, Dr Reddy's recall products in US market due to manufacturing issues

Time of India

timea day ago

  • Time of India

Sun Pharma, Lupin, Dr Reddy's recall products in US market due to manufacturing issues

Domestic drug majors Sun Pharma , Lupin and Dr Reddy's Laboratories are recalling drugs in the US market due to manufacturing issues and product mix up, according to the US health regulator . As per the latest Enforcement Report of US Food and Drug Administration ( USFDA), ), the Mumbai-headquartered Sun Pharmaceutical Industries is recalling 5,448 bottles of a generic medication in the US. Explore courses from Top Institutes in Please select course: Select a Course Category PGDM Operations Management MBA others Data Analytics Cybersecurity Public Policy Management Healthcare Design Thinking MCA Data Science Data Science Product Management Others Artificial Intelligence Degree Project Management Digital Marketing Technology Leadership CXO healthcare Finance Skills you'll gain: Financial Analysis & Decision Making Quantitative & Analytical Skills Organizational Management & Leadership Innovation & Entrepreneurship Duration: 24 Months IMI Delhi Post Graduate Diploma in Management (Online) Starts on Sep 1, 2024 Get Details Princeton-based Sun Pharmaceutical Industries Inc is recalling the affected lot of Lisdexamfetamine Dimesylate capsules (60 mg) due to "Failed Dissolution Specifications", the US health regulator stated. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like How Much Does It Cost to Rent a Private Jet - The Prices May Surprise You! Private Jet I Search Ads Learn More Undo The medication is used to treat attention deficit hyperactivity disorder ( ADHD ). The drug firm initiated the Class II recall in the US on June 16 this year, it added. Live Events Another Mumbai-based drug maker Lupin is recalling 58,968 bottles of a generic combination medication used to treat high blood pressure. Naples-based Lupin Pharmaceuticals Inc is recalling Lisinopril and Hydrochlorothiazide tablets (USP 20mg/12.5mg). The affected lot was manufactured at the company's Nagpur-based manufacturing facility. As per the USFDA, the company initiated the Class II recall on June 20 due to "Product Mix Up". This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg, the US health regulator stated. In another filing, the US health regulator said that Dr Reddy 's Laboratories is recalling 1,476 bottles of Omeprazole Delayed-release capsules. The medication is used to treat certain stomach and esophagus problems. Princeton-based Dr. Reddy's Laboratories , Inc initiated the Class II recall on June 30, 2025, USFDA stated. The affected lot was produced at the company's Bachupally (Telangana)-based manufacturing facility. The recall is due to the presence of foreign tablets/capsules, USFDA said. It is due to the presence of foreign Divalproex Sodium extended-release 250mg tablets in a bottle of omeprazole capsules, it added. As per the USFDA, a Class-II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal.

Sun Pharma, Lupin, Dr Reddys recall products in US market
Sun Pharma, Lupin, Dr Reddys recall products in US market

News18

timea day ago

  • News18

Sun Pharma, Lupin, Dr Reddys recall products in US market

New Delhi, Jul 27 (PTI) Domestic drug majors Sun Pharma, Lupin and Dr Reddy's Laboratories are recalling drugs in the US market due to manufacturing issues and product mix up, according to the US health regulator. As per the latest Enforcement Report of US Food and Drug Administration (USFDA), the Mumbai-headquartered Sun Pharmaceutical Industries is recalling 5,448 bottles of a generic medication in the US. Princeton-based Sun Pharmaceutical Industries Inc is recalling the affected lot of Lisdexamfetamine Dimesylate capsules (60 mg) due to 'Failed Dissolution Specifications", the US health regulator stated. The medication is used to treat attention deficit hyperactivity disorder (ADHD). The drug firm initiated the Class II recall in the US on June 16 this year, it added. Another Mumbai-based drug maker Lupin is recalling 58,968 bottles of a generic combination medication used to treat high blood pressure. Naples-based Lupin Pharmaceuticals Inc is recalling Lisinopril and Hydrochlorothiazide tablets (USP 20mg/12.5mg). The affected lot was manufactured at the company's Nagpur-based manufacturing facility. As per the USFDA, the company initiated the Class II recall on June 20 due to 'Product Mix Up". This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg, the US health regulator stated. In another filing, the US health regulator said that Dr Reddy's Laboratories is recalling 1,476 bottles of Omeprazole Delayed-release capsules. The medication is used to treat certain stomach and esophagus problems. Princeton-based Dr. Reddy's Laboratories, Inc initiated the Class II recall on June 30, 2025, USFDA stated. The affected lot was produced at the company's Bachupally (Telangana)-based manufacturing facility. The recall is due to the presence of foreign tablets/capsules, USFDA said. It is due to the presence of foreign Divalproex Sodium extended-release 250mg tablets in a bottle of omeprazole capsules, it added. As per the USFDA, a Class-II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal. PTI MSS HVA view comments First Published: July 27, 2025, 10:45 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store